# Italy clinical trial activity growth

> Live situation record from CLSTR: https://clstr.news/situations/italy-clinical-trial-activity-growth
> Updated: 2026-08-06T08:41:49.000Z. Sources: 2. Developments: 2.

In mid‑2026 the Italian Medicines Agency (AIFA) released its 2024 national report, noting a record 669 authorised clinical trials – the highest in three years. Commercially‑sponsored studies made up 85 % of the total, while non‑profit trials fell to their lowest level since 2004. Oncology and haematology dominated the portfolio with 248 trials, and the EU Clinical Trial Information System was credited with boosting Italy’s research environment, especially for profit‑driven projects.

A week later, the Emilia‑Romagna regional health network reported an even larger surge, documenting 1,530 clinical studies conducted in 2025 – a regional record. The majority were multicentre and internationally collaborative, with oncology accounting for 28.6 % of the work. Ethics committees issued 1,834 opinions, 98.3 % favourable, underscoring the region’s growing integration into European research networks and its expanding role in precision medicine.

## Timeline

### 2026-08-06: Emilia-Romagna records 1,530 clinical studies in 2025

Emilia‑Romagna’s health network logged a record 1,530 clinical studies in 2025, with most being multicentre and oncology‑focused; ethics committees gave 98.3% favourable opinions.

2 sources. https://clstr.news/cluster/emilia-romagna-records-1530-clinical-studies-in-2025

### 2026-07-28: Italian AIFA reports record 669 clinical trials in 2024

AIFA’s 2024 report shows Italy authorized a record 669 clinical trials, 85% profit‑driven, 15% non‑profit, with oncology leading at 248 studies.

2 sources. https://clstr.news/cluster/italian-aifa-reports-record-669-clinical-trials-in-2024

---
Cite as: Italy clinical trial activity growth. CLSTR, https://clstr.news/situations/italy-clinical-trial-activity-growth